Venlafaxine inhibits the upregulation of plasma tumor necrosis factor-alpha (TNF-α) in the Chinese patients with major depressive disorder: A prospective longitudinal study

Psychoneuroendocrinology

Volumn 38, Issue 1, 2013, Pages 107-114

  Li, Zezhi ^a   Qi, Dake ^b   Chen, Jun ^a   Zhang, Chen ^a   Yi, Zhenghui ^a   Yuan, Chengmei ^a   Wang, Zuowei ^a,c   Hong, Wu ^a   Yu, Shunying ^a   Cui, Donghong ^a   Fang, Yiru ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Mental Health Centre of Hongkou District   (China)

Author keywords

Major depression; Suicide; Tumor necrosis factor alpha; Venlafaxine

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; VENLAFAXINE;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INHIBITION; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION;

ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ASIAN CONTINENTAL ANCESTRY GROUP; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SUICIDAL IDEATION; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; YOUNG ADULT;

EID: 84870388281     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2012.05.005     Document Type: Article

References (39)

1. Anisman H., Merali Z., Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog. Neurobiol. 2008, 85:1-74.
2. Boomsma D.I., Willemsen G., Sullivan P.F., Heutink P., Meijer P., Sondervan D., Kluft C., Smit G., Nolen W.A., Zitman F.G., Smit J.H., Hoogendijk W.J., van Dyck R., de Geus E.J., Penninx B.W. Genome-wide association of major depression: description of samples for the GAIN Major Depressive Disorder Study: NTR and NESDA biobank projects. Eur. J. Hum. Genet. 2008, 16:335-342.
3. Borges G., Orozco R., Rafful C., Miller E., Breslau J. Suicidality, ethnicity and immigration in the USA. Psychol. Med. 2011, 26:1-10.
4. Bosker F.J., Hartman C.A., Nolte I.M., Prins B.P., Terpstra P., Posthuma D., van Veen T., Willemsen G., DeRijk R.H., de Geus E.J., Hoogendijk W.J., Sullivan P.F., Penninx B.W., Boomsma D.I., Snieder H., Nolen W.A. Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol. Psychiatry 2011, 16:516-532.
5. Ching S., Zhang H., Belevych N., He L., Lai W., Pu X.A., Jaeger L.B., Chen Q., Quan N. Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration. J. Neurosci. 2007, 27:10476-10486.
6. Dantzer R. Cytokine-induced sickness behavior: where do we stand?. Brain Behav. Immun. 2001, 15:7-24.
7. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
8. Eller T., Vasar V., Shlik J., Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:445-450.
9. Ertenli I., Ozer S., Kiraz S., Apras S.B., Akdogan A., Karadag O., Calguneri M., Kalyoncu U. Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol. Int. 2012, 32:323-330.
10. Fang Y.R., Yuan C.M., Xu Y.F., Chen J., Wu Z.G., Cao L., Yi Z., Hong W., Wang Y., Jiang K., Gao K., Cui X., Nierenberg A.A., OPERATION Study Team Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression. A double-blind, randomized pilot study in a Chinese population. J. Clin. Psychopharmacol. 2010, 30:357-364.
11. Felger J.C., Alagbe O., Hu F., Mook D., Freeman A.A., Sanchez M.M., Kalin N.H., Ratti E., Nemeroff C.B., Miller A.H. Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol. Psychiatry 2007, 62:1324-1333.
12. Fornaro M., Martino M., Battaglia F., Colicchio S., Perugi G. Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60mg/day: a preliminary observation. Neuropsychiatr. Dis. Treat. 2011, 7:51-56.
13. Gabbay V., Klein R.G., Guttman L.E., Babb J.S., Alonso C.M., Nishawala M., Katz Y., Gaite M.R., Gonzalez C.J. A preliminary study of cytokines in suicidal and nonsuicidal adolescents with major depression. J. Child Adolesc. Psychopharmacol. 2009, 19:423-430.
14. Hannestad J., Dellagioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36:2452-2459.
15. Himmerich H., Binder E.B., Kunzel H.E., Schuld A., Lucae S., Uhr M., Pollmächer T., Holsboer F., Ising M. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol. Psychiatry 2006, 60:882-888.
16. Himmerich H., Fulda S., Linseisen J., Seiler H., Wolfram G., Himmerich S., Gedrich K., Kloiber S., Lucae S., Ising M., Uhr M., Holsboer F., Pollmächer T. Depression, comorbidities and the TNF-alpha system. Eur. Psychiatry 2008, 23:421-429.
17. Huang C.J., Stewart J.K., Franco R.L., Evans R.K., Lee Z.P., Cruz T.D., Webb H.E., Acevedo E.O. LPS-stimulated tumor necrosis factor-alpha and interleukin-6 mRNA and cytokine responses following acute psychological stress. Psychoneuroendocrinology 2011, 36:1553-1561.
18. Jacobson L.H., Cryan J.F. Feeling strained? Influence of genetic background on depression-related behavior in mice: a review. Behav. Genet. 2007, 37:171-213.
19. Janelidze S., Mattei D., Westrin A., Traskman-Bendz L., Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav. Immun. 2011, 25:335-339.
20. Kaster M.P., Gadotti V.M., Calixto J.B., Santos A.R., Rodrigues A.L. Depressive-like behavior induced by tumor necrosis factor-alpha in mice. Neuropharmacology 2012, 62:419-426.
21. Kelley K.W., Bluthe R.M., Dantzer R., Zhou J.H., Shen W.H., Johnson R.W., Broussard S.R. Cytokine-induced sickness behavior. Brain Behav. Immun. 2003, 17:S112-S118.
22. Kempermann G., Kronenberg G. Depressed new neurons-adult hippocampal neurogenesis and a cellular plasticity hypothesis of major depression. Biol. Psychiatry 2003, 54:499-503.
23. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S., National Comorbidity Survey Replication The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
24. Kraus T., Haack M., Schuld A., Hinze-Selch D., Koethe D., Pollmacher T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 2002, 35:220-225.
25. Larney S., Topp L., Indig D., O'Driscoll C., Greenberg D. A cross-sectional survey of prevalence and correlates of suicidal ideation and suicide attempts among prisoners in New South Wales, Australia. BMC Public Health 2012, 12:14.
26. Lin K.M. Biological differences in depression and anxiety across races and ethnic groups. J. Clin. Psychiatry 2001, 62:S13-S19.
27. Liu Y., Ho R.C., Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J. Affect. Disord. 2011, e-pub ahead of print 25 August 2011. 10.1016/j.jad.2011.08.003.
28. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
29. Narita K., Murata T., Takahashi T., Kosaka H., Omata N., Wada Y. Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:1159-1162.
30. O'Connor J.C., Andre C., Wang Y., Lawson M.A., Szegedi S.S., Lestage J., Castanon N., Kelley K.W., Dantzer R. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J. Neurosci. 2009, 29:4200-4209.
31. Pavon L., Sandoval-Lopez G., Eugenia Hernandez M., Loria F., Estrada I., Perez M., Moreno J., Avila U., Leff P., Antón B., Heinze G. Th2 cytokine response in major depressive disorder patients before treatment. J. Neuroimmunol. 2006, 172:156-165.
32. Piletz J.E., Halaris A., Iqbal O., Hoppensteadt D., Fareed J., Zhu H., Sinacore J., Devane C.L. Pro-inflammatory biomakers in depression: treatment with venlafaxine. World J. Biol. Psychiatry 2009, 10:313-323.
33. Simon N.M., McNamara K., Chow C.W., Maser R.S., Papakostas G.I., Pollack M.H., Nierenberg A.A., Fava M., Wong K.K. A detailed examination of cytokine abnormalities in major depressive disorder. Eur. Neuropsychopharmacol. 2008, 18:230-233.
34. Steiner J., Bielau H., Brisch R., Danos P., Ullrich O., Mawrin C., Bernstein H.G., Bogerts B. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res. 2008, 42:151-157.
35. Tuglu C., Kara S.H., Caliyurt O., Vardar E., Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003, 170:429-433.
36. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., Cella D., Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
37. Vollmar P., Nessler S., Kalluri S.R., Hartung H.P., Hemmer B. The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int. J. Neuropsychopharmacol. 2009, 12:525-536.
38. Waldman S.V., Blumenthal J.A., Babyak M.A., Sherwood A., Sketch M., Davidson J., Watkins L.L. Ethnic differences in the treatment of depression in patients with ischemic heart disease. Am. Heart J. 2009, 157:77-83.
39. Yoshimura R., Hori H., Ikenouchi-Sugita A., Umene-Nakano W., Ueda N., Nakamura J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:722-726.